Gene and cell therapies, biologics, vaccines

Oculgen (Shen Zhen Oculgen BioMedical Technology Co., Ltd.) focuses on developing innovative biomedical technologies aimed at addressing various ocular diseases. The company emphasizes its commitment to advancing therapeutic solutions through a robust pipeline of products that leverage cutting-edge research and development. Their technologies are designed to enhance the efficacy of treatments for conditions such as retinal diseases, glaucoma, and other vision impairments, showcasing a dedication to improving patient outcomes in the field of ophthalmology.

The company employs a range of advanced methodologies, including gene therapy and regenerative medicine, to create novel treatment options. Oculgen's research is grounded in a deep understanding of ocular biology and pathology, allowing them to target specific mechanisms of disease. By integrating scientific expertise with technological innovation, Oculgen aims to deliver transformative therapies that not only address existing ocular health challenges but also pave the way for future advancements in eye care.

China

Oculgen Biopharma (Shen Zhen Oculgen BioMedical Technology Co. ,Ltd.) has a portfolio of the latest and best breakthrough ophthalmic treatment technology products covering the stages from early new drug target discovery, independent innovation, and commercialization. It hopes to address unmet clinical needs in the field of ophthalmic diseases and benefit global ophthalmic patients by providing innovative drugs in China, Asia, and around the world.

Eye Diseases

Room B808, Yunzhongcheng, Building 1, Phase 6, Vanke Yuncheng, Dashi 2nd Road, Xili Community, Xili Street, Nanshan District, Shenzhen, China

Oculgen (Shen Zhen Oculgen BioMedical Technology Co. ,Ltd.)

Company Details